Minutes: unconfirmed

Guideline Development Group Meeting: ACS, GDG 2

Date and Time: 10.30-4.30pm, Thursday 5 June 2008

Place: National Collaborating Centre for Chronic Conditions
       Royal College of Physicians
       11 St Andrew’s Place
       Regent’s Park
       London
       NW1 4LE

Present:

GDG members
John Camm          GDG Chair
Huon Gray          Clinical Advisor
Sotiris Antoniou  Pharmacy representative
Lina Bakhshi       NCC-CC Information Scientist
Jenny Cadman       CCU nurse representative
Emily Crowe        NCC-CC Research fellow
Mark de Belder     Cardiologist representative
Rob Grant          NCC-CC Project manager
Rob Henderson      Cardiologist representative
Kate Lovibond      NCC-CC Health economist
Gavin Maxwell      Patient and carer representative
Francis Morris     A&E Physician representative
Alun Roebuck       Nurse representative
Claire Turner      NCC-CC Project Manager
Richard Underwood  Cardiac imaging representative

Not present:
Charles Kingdom    Ambulance service representative
David Taggart      Cardiac surgeon representative

In attendance:
Bernard Higgins    NCC-CC Clinical Director
Sue Latchem        NICE Commissioning Manager
Jill Parnham       NCC-CC Manager
Nicola Sloan       NCC-CC Research Fellow
Dave Wonderling    NCC-CC Senior health economist

Notes

Welcome

1. JC welcomed the group and RG introduced Claire Turner, who is taking over the
The National Collaborating Centre for Chronic Conditions is funded to produce guidelines for the NHS by the National Institute for Health and Clinical Excellence.

A partnership of organisations providing care for chronic conditions.

project management of this guideline after this meeting. The Declarations of Interests register was made available to the GDG chair. The chair requested updates to the existing declarations of interests from GDG members; no new declarations were received. A new form was received from Kate Lovibond. The chair reviewed the existing declarations of interest and deemed that none were in conflict with the agenda topics and clinical questions under discussion at the meeting.

Notes

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting. A number of typographical changes were made.

3. The GDG reviewed the draft clinical questions and results from the first on-line prioritisation survey. Revisions to the questions were noted to be fed into a second on-line prioritisation survey, given the number of GDG members absent from this meeting.

4. Areas for potential health economic analysis were discussed and agreed by the group.

5. The draft guideline sections for treatment with clopidogrel and glycoprotein 2b/3a inhibitors were reviewed by the group and a number of minor changes were agreed by the group.

6. The GDG discussed the clinical and health economic evidence tables and statements, and formulate recommendations for the following:
   - synthetic pentasaccharides
   - direct thrombin inhibitors

GDG4 was confirmed as 31 July 2008. GDG10 was confirmed as 22 January 2009. CT will send round an updated list of meetings.

Next meeting: 2nd GDG meeting (GDG2), 3rd July 2008, 10:30 – 16.30, Rosenheim & Pickering Rooms, RCP